GENENTA SCIENCE(SP.ADR)/1 (K5F) - Net Assets
Based on the latest financial reports, GENENTA SCIENCE(SP.ADR)/1 (K5F) has net assets worth €21.84 Million EUR (≈ $25.53 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€31.89 Million ≈ $37.28 Million USD) and total liabilities (€10.05 Million ≈ $11.75 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See GENENTA SCIENCE(SP.ADR)/1 balance sheet quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €21.84 Million |
| % of Total Assets | 68.49% |
| Annual Growth Rate | -13.42% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 46.35 |
GENENTA SCIENCE(SP.ADR)/1 - Net Assets Trend (2021–2025)
This chart illustrates how GENENTA SCIENCE(SP.ADR)/1's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see K5F stock market capitalisation.
Annual Net Assets for GENENTA SCIENCE(SP.ADR)/1 (2021–2025)
The table below shows the annual net assets of GENENTA SCIENCE(SP.ADR)/1 from 2021 to 2025. Also explore K5F year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €21.84 Million ≈ $25.53 Million |
+74.79% |
| 2024-12-31 | €12.50 Million ≈ $14.61 Million |
-38.84% |
| 2023-12-31 | €20.43 Million ≈ $23.89 Million |
-34.38% |
| 2022-12-31 | €31.14 Million ≈ $36.40 Million |
-19.87% |
| 2021-12-31 | €38.86 Million ≈ $45.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GENENTA SCIENCE(SP.ADR)/1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3556554000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €84.43 Million | 386.55% |
| Total Equity | €21.84 Million | 100.00% |
GENENTA SCIENCE(SP.ADR)/1 Competitors by Market Cap
The table below lists competitors of GENENTA SCIENCE(SP.ADR)/1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bodhi Tree Multimedia Limited
NSE:BTML
|
$14.25 Million |
|
BBI Development S.A.
WAR:BBD
|
$14.25 Million |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
$14.25 Million |
|
Spirent Communications plc
LSE:SPT
|
$14.25 Million |
|
Ryukil C&S Ltd
KQ:191410
|
$14.23 Million |
|
Beeio Honey Ltd
TA:WTS
|
$14.22 Million |
|
Lancartama Sejati Tbk
JK:TAMA
|
$14.20 Million |
|
Magnum Ventures Limited
NSE:MAGNUM
|
$14.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GENENTA SCIENCE(SP.ADR)/1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,495,706 to 21,840,640, a change of 9,344,934 (74.8%).
- Net loss of 6,529,827 reduced equity.
- Other factors increased equity by 15,874,761.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-6.53 Million | -29.9% |
| Other Changes | €15.87 Million | +72.68% |
| Total Change | €- | 74.79% |
Book Value vs Market Value Analysis
This analysis compares GENENTA SCIENCE(SP.ADR)/1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.56x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.24x to 0.56x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.13 | €0.52 | x |
| 2022-12-31 | €1.71 | €0.52 | x |
| 2023-12-31 | €1.12 | €0.52 | x |
| 2024-12-31 | €0.68 | €0.52 | x |
| 2025-12-31 | €0.93 | €0.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GENENTA SCIENCE(SP.ADR)/1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.46x
- Recent ROE (-29.90%) is above the historical average (-39.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -14.23% | 0.00% | 0.00x | 1.03x | €-9.42 Million |
| 2022 | -27.23% | 0.00% | 0.00x | 1.07x | €-11.59 Million |
| 2023 | -57.00% | 0.00% | 0.00x | 1.09x | €-13.69 Million |
| 2024 | -71.32% | 0.00% | 0.00x | 1.19x | €-10.16 Million |
| 2025 | -29.90% | 0.00% | 0.00x | 1.46x | €-8.71 Million |
Industry Comparison
This section compares GENENTA SCIENCE(SP.ADR)/1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $349,324,258
- Average return on equity (ROE) among peers: -68.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GENENTA SCIENCE(SP.ADR)/1 (K5F) | €21.84 Million | -14.23% | 0.46x | $14.25 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $213.00 Million | -25.91% | 0.79x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $242.58 Million | -85.63% | 0.52x | $189.29 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $825.52 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.05 Billion | -42.40% | 0.17x | $1.82 Billion |
About GENENTA SCIENCE(SP.ADR)/1
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more